FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?

AbbVie $ABBV has obtained FDA approval to administer its Mavyret hepatitis C pill as a two-month regimen, versus the 12-week course it was originally cleared for — a move that may help expand options for the margin of covered patients who need a shorter regimen.